Health

Scholar claims that regulatory sandboxes such as emergency use authorizations boost innovation, but at a cost.

FDA warns consumers to protect themselves from a known carcinogen in hair smoothing products.

Scholars examine the effectiveness of the contentious 340B Drug Pricing Program.

A controversial approval of an Alzheimer’s treatment reveals a core weakness in oversight of agency discretion.

COVID-19 highlights a blood donation deferral policy that clashes with modern science.

Government watchdog finds that FDA is not properly inspecting imported seafood.

State policies create and exacerbate barriers to access rural health care.

Lawyer proposes a new legal framework for reviewing FDA’s refusal to regulate lethal injection drugs.

Contrary to longstanding precedent, individualism reigns supreme in recent legal decisions over COVID-19.

Scholar explains why the DEA—not FDA—has power over the classification of potentially addictive substances.

FDA faces mounting pressure from advocacy groups claiming a high chemical content in macaroni and cheese.

Science is vital for effective risk governance but so too is public engagement.